US vaccines specialist Novavax (Nasdaq: NVAX) has applied to the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain to expand the authorization of Nuvaxovid (NVX-CoV2373) COVID-19 Vaccine (recombinant, adjuvanted), to adolescents aged 12 through 17 years.
The MHRA previously granted conditional marketing authorization (CMA) for Nuvaxovid in individuals 18 years of age and older in February 2022. The vaccine is given as a primary vaccination in two doses administered 21 days apart.
If the new submission for approval is granted, Nuvaxovid would be the first protein-based COVID-19 vaccine option authorized for adolescents in Great Britain.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze